Skip to main content
. 2020 Jan 2;31(2):435–446. doi: 10.1681/ASN.2019070676

Figure 2.

Figure 2.

Clinical features of ICPi-AKI, stratified by AKI severity. (A) The frequency of concomitant potential TIN-causing medications taken within 2 weeks preceding ICPi-AKI. (B–F) The distribution of eosinophilia, proteinuria, dipstick hematuria, leukocyte esterase, and pyuria in patients with ICPi-AKI, respectively. Abx, antibiotic; HPF, high-power field; Neg, negative; UA, urinalysis; UPCR, urine protein-to-creatinine ratio; WBCs, white blood cells.